Zacks Research Issues Pessimistic Outlook for VRTX Earnings
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) – Equities researchers at Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for shares of Vertex Pharmaceuticals in a research note issued to investors on Monday, March 3rd. Zacks Research analyst R. Department now anticipates that the pharmaceutical company will earn $4.13 per share for […]
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) – Equities researchers at Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for shares of Vertex Pharmaceuticals in a research note issued to investors on Monday, March 3rd. Zacks Research analyst R. Department now anticipates that the pharmaceutical company will earn $4.13 per share for […]
